Vaccine Development

Sabin Vaccine Development Capabilties

With ten years of experience, Sabin Vaccine Development has produced a well-rounded model that serves as a blueprint for the development of safe and effective vaccines against infectious and neglected tropical diseases. Existing capabilties include:

• Read more

History of the Schistosomiasis Vaccine Initiative

The Schistosomiasis Vaccine Initiative (SVI) was launched in 2008 through funding from Mr. Morton Hyman and the Blavatnik Charitable Foundation. In collaboration with researchers at James Cook University and The George Washington University, a promising antigen, Sm-TSP-2, was selected for development.

Timeline

November 2007
Sabin Vaccine Development receives its initial funding from private donors to establish SVI and develop the Sm-TSP-2 Schistosomiasis Vaccine.

March 2008

• Read more

Leading Health Experts Urge Turkish, Global Policy Leaders To Take Action Against Pneumococcal Disease

February 13, 2008

ISTANBUL, TURKEY, 15 February 2008 – Leading health experts gathered in Istanbul today to call upon policy leaders in Turkey and in the region to assure access to pneumococcal vaccines and to support the expansion of health systems to deliver them and monitor their impact.

• Read more